A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients
NCT ID: NCT04139252
Last Updated: 2023-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
250 participants
OBSERVATIONAL
2020-03-17
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA
NCT04763148
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
NCT01478269
Italian Study of Patients With Lymphoma
NCT06814925
Study on Plasmablastic Lymphoma Patients
NCT06781359
The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study
NCT05169203
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to collect liquid biopsy samples of patients with newly diagnosed DLBCL/HGBCL to develop a blood based assay allowing biomarker driven treatment in the future.
The secondary objectives are to collect clinical data and pre-treatment tissue samples (for determining molecular profiles) to allow for correlation to the blood based assay.
This study is designed for patients with newly diagnosed DLBCL and HGBCL ≥ 18 yr.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ann Arbor stage II-IV
* Patients intended to be treated with 6 cycles R-CHOP (or DA-EPOCH-R) as first-line treatment (successive inclusion in HOVON 151 or HOVON 152 is possible)
* Age ≥ 18 years
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stichting Hemato-Oncologie voor Volwassenen Nederland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
M.E.D. Chamuleau, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
VUmc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NL-Den Bosch-JBZ
's-Hertogenbosch, , Netherlands
NL-Alkmaar-NWZ
Alkmaar, , Netherlands
NL-Almelo-ZGTALMELO
Almelo, , Netherlands
NL-Almere-FLEVOZIEKENHUIS
Almere Stad, , Netherlands
NL-Amersfoort-MEANDERMC
Amersfoort, , Netherlands
NL-Amstelveen-AMSTELLAND
Amstelveen, , Netherlands
NL-Amsterdam-AMC
Amsterdam, , Netherlands
NL-Amsterdam-OLVG
Amsterdam, , Netherlands
NL-Amsterdam-VUMC
Amsterdam, , Netherlands
NL-Arnhem-RIJNSTATE
Arnhem, , Netherlands
NL-Assen-WZA
Assen, , Netherlands
NL-Beverwijk-RKZ
Beverwijk, , Netherlands
NL-Breda-AMPHIA
Breda, , Netherlands
NL-Capelle a/d IJssel-YSL
Capelle aan den IJssel, , Netherlands
NL-Delft-RDGG
Delft, , Netherlands
NL-Deventer-DZ
Deventer, , Netherlands
NL-Dirksland-VANWEELBETHESDA
Dirksland, , Netherlands
NL-Doetinchem-SLINGELAND
Doetinchem, , Netherlands
NL-Dordrecht-ASZ
Dordrecht, , Netherlands
NL-Ede-ZGV
Ede, , Netherlands
NL-Eindhoven-CATHARINA
Eindhoven, , Netherlands
NL-Eindhoven-MAXIMAMC
Eindhoven, , Netherlands
NL-Emmen-SCHEPER
Emmen, , Netherlands
NL-Enschede-MST
Enschede, , Netherlands
NL-Geldrop-STANNA
Geldrop, , Netherlands
NL-Goes-ADRZ
Goes, , Netherlands
NL-Gorinchem-BEATRIX
Gorinchem, , Netherlands
NL-Gouda-GROENEHART
Gouda, , Netherlands
NL-Groningen-UMCG
Groningen, , Netherlands
NL-Hardenberg-SAXENBURGH
Hardenberg, , Netherlands
NL-Harderwijk-STJANSDALHARDERWIJK
Harderwijk, , Netherlands
NL-Heerenveen-TJONGERSCHANS
Heerenveen, , Netherlands
NL-Helmond-ELKERLIEK
Helmond, , Netherlands
NL-Hoofddorp-SPAARNEGASTHUIS
Hoofddorp, , Netherlands
NL-Hoorn-DIJKLANDERHOORN
Hoorn, , Netherlands
NL-Leeuwarden-MCL
Leeuwarden, , Netherlands
NL-Leiden-LUMC
Leiden, , Netherlands
NL-Maastricht-MUMC
Maastricht, , Netherlands
NL-Nieuwegein-ANTONIUS
Nieuwegein, , Netherlands
NL-Nijmegen-CWZ
Nijmegen, , Netherlands
NL-Roermond-LZR
Roermond, , Netherlands
NL-Roosendaal-BRAVIS
Roosendaal, , Netherlands
NL-Rotterdam-ERASMUSMC
Rotterdam, , Netherlands
NL-Rotterdam-IKAZIA
Rotterdam, , Netherlands
NL-Rotterdam-MAASSTADZIEKENHUIS
Rotterdam, , Netherlands
NL-Rotterdam-SFG
Rotterdam, , Netherlands
NL-Sneek-ANTONIUSSNEEK
Sneek, , Netherlands
NL-Spijkenisse-SPIJKENISSEMC
Spijkenisse, , Netherlands
NL-Terneuzen-ZORGSAAM
Terneuzen, , Netherlands
NL-Den Haag-HAGA
The Hague, , Netherlands
NL-Den Haag-HMCWESTEINDE
The Hague, , Netherlands
NL-Tiel-RIVIERENLAND
Tiel, , Netherlands
NL-Tilburg-ETZ
Tilburg, , Netherlands
NL-Uden-BERNHOVEN
Uden, , Netherlands
NL-Utrecht-DIAKONESSENUTRECHT
Utrecht, , Netherlands
NL-Utrecht-UMCUTRECHT
Utrecht, , Netherlands
NL-Venlo-VIECURI
Venlo, , Netherlands
NL-Winterswijk-SKBWINTERSWIJK
Winterswijk, , Netherlands
NL-Zutphen-GELREZUTPHEN
Zutphen, , Netherlands
NL-Zwolle-ISALA
Zwolle, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HO902
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.